IP Library Granted Patent US 9,433,630
Granted Patent B1
US 9,433,630 · App. 15/135,259 · Granted Sep 6, 2016

Topical formulations comprising a steroid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,433,630
App. No.
15/135,259
Granted
Sep 6, 2016
Kind
B1
Abstract

The application provides formulations for the topical administration of an active agent comprising at least one steroid, in the form of topical sprays that are propellant-free, and/or substantially non-foaming, and/or alcohol-free. The present application also provides processes for preparing such compositions and methods of using them in management of skin diseases or disorders such as psoriasis, dermatoses, and other associated skin diseases or disorders.

Claims (47)

1. A sprayable topical pharmaceutical composition, comprising:

an active agent consisting of at least one steroid;

a non-polymeric emulsifying agent comprising sorbitan stearate;

a polymer selected from the group consisting of a cellulose, a gum, an alginate, and a phthalate;

water; and

a water-immiscible substance;

wherein said composition is substantially free of a propellant and propylene glycol; and

wherein the topical pharmaceutical composition is substantially non-occlusive to the skin.

2. The composition according to claim 1 , wherein the steroid is selected from the group comprising alclometasone dipropionate, beclomethasone dipropionate, betamethasone dipropionate, betamethasone valerate, fluocinolone acetonide, halobetasol propionate, hydrocortisone aceponate, hydrocortisone acetate, hydrocortisone valerate, hydrocortisone butyrate, mometasone furoate, triamcinolone acetonide, clocortolone pivalate, clobetasol propionate, desoximetasone, and fluticasone propionate.

3. The composition according to claim 1 , wherein the polymer is selected from the group consisting of ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, hydroxybutyl methyl cellulose, xanthan gum, tragacanth, guar gum, locust bean gum, acacia, alginate, cellulose acetate phthalate, cellulose acetate butyrate, hydroxypropyl methylcellulose phthalate, and any combination thereof.

4. The composition according to claim 1 , wherein the water-immiscible substance is selected from the group consisting of vegetable oil, saturated paraffin oil, mineral oil, fatty acid, fatty ester of a natural fatty acid, triglyceride of animal or vegetable origin, medium chain triglyceride, mixture of mono-, di- and/or tri-glycerides, wax, hydrogenated vegetable oil, and any combination thereof.

5. The composition according to claim 1 , and further comprising a penetration enhancer.

6. The composition according to claim 5 , wherein the penetration enhancer is in amounts of about 0.001 percent to about 15 percent by weight.

7. The composition according to claim 6 , wherein the penetration enhancer is selected from the group comprising a polyol and esters, ethers, sulfoxides, fatty acids, fatty acid esters, or any combination thereof.

8. The composition according to claim 1 , wherein

the steroid is selected from the group comprising alclometasone dipropionate, beclomethasone dipropionate, betamethasone dipropionate, betamethasone valerate, fluocinolone acetonide, halobetasol propionate, hydrocortisone aceponate, hydrocortisone acetate, hydrocortisone valerate, hydrocortisone butyrate, mometasone furoate, triamcinolone acetonide, clocortolone pivalate, clobetasol propionate, desoximetasone, or fluticasone propionate;

the polymer is selected from the group consisting of ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxybutyl methyl cellulose, xanthan gum, tragacanth, guar gum, locust bean gum, acacia, alginate, cellulose acetate phthalate, cellulose acetate butyrate, hydroxypropyl methylcellulose phthalate, and any combination thereof; and

the water-immiscible substance is selected from the group consisting of vegetable oil, saturated paraffin oil, mineral oil, fatty acid, fatty ester of a natural fatty acid, triglyceride of animal or vegetable origin, medium chain triglyceride, mixture of mono-, di- and/or tri-glycerides, wax, hydrogenated vegetable oil, and any combination thereof.

9. The composition according to claim 1 , wherein

the steroid is selected from the group comprising betamethasone dipropionate and betamethasone valerate; and

the polymer is selected from the group consisting of ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxybutyl methyl cellulose, and any combination thereof.

10. The composition according to claim 1 , wherein the steroid is betamethasone dipropionate.

11. The composition according to claim 1 , wherein the viscosity of the composition is in the range of about 10 to about 15,000 centipoise.

12. The composition according to claim 1 , wherein the composition is substantially non-foaming.

13. A sprayable topical pharmaceutical composition, comprising:

a betamethasone compound;

a non-polymeric emulsifying agent comprising sorbitan stearate;

a polymer selected from the group consisting of a cellulose, a gum, an alginate, and a phthalate;

water;

a water-immiscible substance; and

wherein said composition is substantially free of a propellant and propylene glycol; and

wherein the topical pharmaceutical composition is substantially non-occlusive to the skin.

14. The composition according to claim 13 , wherein the betamethasone compound is in amounts equivalent to about 0.025 to about 0.1 percent by weight of betamethasone base.

15. The composition according to claim 13 , wherein the betamethasone compound is betamethasone benzoate, betamethasone dipropionate, betamethasone sodium phosphate, or betamethasone valerate.

16. The composition according to claim 13 , wherein the polymer is selected from the group consisting of ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, hydroxybutyl methyl cellulose, xanthan gum, tragacanth, guar gum, locust bean gum, acacia, alginate, cellulose acetate phthalate, cellulose acetate butyrate, hydroxypropyl methylcellulose phthalate, and any combination thereof.

17. The composition according to claim 13 , wherein the water-immiscible substance is selected from the group consisting of vegetable oil, saturated paraffin oil, mineral oil, fatty acid, fatty ester of a natural fatty acid, triglyceride of animal or vegetable origin, medium chain triglyceride, mixture of mono-, di- and/or tri-glycerides, wax, hydrogenated vegetable oil, and any combination thereof.

18. The composition according to claim 13 , and further comprising a penetration enhancer.

19. The composition of claim 18 , wherein the penetration enhancer is in amounts of about 0.001 percent to about 15 percent by weight.

20. The composition according to claim 13 , wherein

the betamethasone compound is betamethasone benzoate, betamethasone dipropionate, betamethasone sodium phosphate, or betamethasone valerate;

the polymer is selected from the group consisting of ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxybutyl methyl cellulose, xanthan gum, tragacanth, guar gum, locust bean gum, acacia, alginate, cellulose acetate phthalate, cellulose acetate butyrate, hydroxypropyl methylcellulose phthalate, and any combination thereof; and

the water-immiscible substance is selected from the group consisting of vegetable oil, saturated paraffin oil, mineral oil, fatty acid, fatty ester of a natural fatty acid, triglyceride of animal or vegetable origin, medium chain triglyceride, mixture of mono-, di- and/or tri-glycerides, wax, hydrogenated vegetable oil, and any combination thereof.

21. The composition according to claim 13 , wherein the betamethasone compound is betamethasone dipropionate; and the polymer is selected from the group consisting of ethyl cellulose, methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxybutyl methyl cellulose, and any combination thereof.

22. The composition according to claim 1 , wherein the viscosity of the composition is in the range of about 10 to about 15,000 centipoise.

23. The composition according to claim 13 , wherein the composition is substantially non-foaming.

24. A method of treating a skin condition comprising administering pharmaceutically effective amount of the composition according to claim 1 to a subject in need thereof, wherein the condition is selected from one or more of atopic dermatitis, seborrhoeic dermatitis, eczema, plaque psoriasis, erythroderma psoriasis, and psoriasis of the scalp, steroid responsive dermatoses, erythema, or contact sensitivity reactions, and other associated diseases or disorders.

25. A method of treating a skin condition comprising administering pharmaceutically effective amount of the composition according to claim 13 to a subject in need thereof, wherein the condition is selected from one or more of atopic dermatitis, seborrhoeic dermatitis, eczema, plaque psoriasis, erythroderma psoriasis, and psoriasis of the scalp, steroid responsive dermatoses, erythema, or contact sensitivity reactions, and other associated diseases or disorders.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2021
From: ENCORE DERMATOLOGY, INC.
To: PRIMUS PHARMACEUTICALS, INC.
Reel/Frame 055576/0523 →
SECURITY INTEREST Recorded Nov 11, 2020
From: HORIZON TECHNOLOGY FINANCE CORPORATION
To: PENNRX VENTURES, LLC
Reel/Frame 054337/0330 →
SECURITY INTEREST Recorded Apr 22, 2019
From: ENCORE DERMATOLOGY, INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 048958/0284 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 19, 2019
From: PROMIUS PHARMA, LLC
To: ENCORE DERMATOLOGY, INC.
Reel/Frame 048941/0640 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2017
From: DR. REDDY'S LABORATORIES LTD.
To: PROMIUS PHARMA LLC
Reel/Frame 042704/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2017
From: UBAIDULLA, UDHUMANSHA; KANDAVILLI, SATEESH; VAIRALE, AJAY SUNIL; WAYNE, JEFFREY A.; NALAMOTHU, VIJENDRA; MEGHAL, MISTRY; PAKUNLU, REFIKA ISIL
To: DR. REDDY'S LABORATORIES LTD
Reel/Frame 041101/0366 →